South Korea's Kospi jumped over 12% Thursday, staging a sharp rebound from its worst session, and on course to clock its best ...
China sets lowest growth target on record at 4.5% to 5%. War powers vote fails in the U.S. Senate. Iran targets Amazon's ...
Texas Republican Rep. Tony Gonzales has come under fire for allegedly having a romantic relationship with a staffer who died ...
4hOpinion
Cramer says the oil market is signaling the Iran war won't spiral — and that's bullish for stocks
CNBC's Jim Cramer said the oil market may be signaling the war with Iran won't escalate into a prolonged disruption to crude ...
CNBC's Jim Cramer discusses the day's market action, the stocks he's watching and more. Got a confidential news tip? We want ...
The Foundation for Angelman Syndrome Therapeutics (FAST) has helped redefine the role of advocacy groups. Founded and led by ...
Personalized therapies, faster diagnoses, and a renewed and previously unimaginable sense of hope for rare disease families.
As scientific and political pressures collide at the FDA, regulatory bottlenecks are intensifying. At this critical and ...
The science behind rare disease treatments is advancing at an unprecedented pace. Biogen is sharpening its long-term strategy ...
Sarepta has come under scrutiny over Elevidys, its gene therapy for Duchenne Muscular Dystrophy (DMD). With a one-time ...
CNBC’s Jim Cramer talks about Target's stock performance, its recent earnings report and what he thinks of the retailer's ...
CNBC's Jim Cramer talks with George Kurtz, founder and CEO of CrowdStrike, to discuss the company's outlook, stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results